6/29/23, 1:09 AM RECOVERY (dexamethasone) Pathway Feedback Search Clinical Topics Home Studies RECOVERY (dexamethasone) RECOVERY (dexamethasone) Disease COVID 19 infection Trial question What is the effect of dexamethasone in patients hospitalized with severe COVID-19? Study design Single center Open label RCT Population Characteristics of study participants 36.0% female N = 6425 64.0% male 6425 patients (2338 female, 4087 male) Inclusion criteria: hospitalized patients with severe COVID-19 Key exclusion criteria: unavailability of dexamethasone, clinical judgement of patients' unsuitability for randomization Interventions N=2104 dexamethasone therapy (oral or IV dexamethasone for up to 10 days) N=4321 no dexamethasone (standard of care) Primary outcome Death at 28 days 25.7 25 7 % https://web.pathway.md/studies/recTe4qpX9Bzb2GZf 1/2 6/29/23, 1:09 AM 25.7 % RECOVERY (dexamethasone) Pathway 5 22.9 19.3 % 12.8 % Significant decrease 6.4 % NNT = 36 0.0 % Dexamethasone therapy No dexamethasone Significant decrease in death at 28 days (22.9% vs. 25.7%; RR 0.83, 95% CI 0.75 to 0.93) Secondary outcomes Borderline significant increase in discharge from hospital within 28 days (12 vs. 13; RR 1.1, 95% CI 1.03 to 1.17) Borderline significant decrease in invasive mechanical ventilation (5.7% vs. 7.8%; RR 0.77, 95% CI 0.62 to 0.95) Conclusion In hospitalized patients with severe COVID-19, dexamethasone therapy was superior to no dexamethasone with respect to death at 28 days. Reference RECOVERY Collaborative Group, Peter Horby, Wei Shen Lim et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. Open reference URL https://web.pathway.md/studies/recTe4qpX9Bzb2GZf 2/2